UK

Kyrexa are developing a groundbreaking kinder cancer treatment for dogs, free from the drawbacks of traditional chemotherapy treatments. 

What do we do?

Kyrexa was co-founded by Clare Knottenbelt a RCVS specialist in Small Animal Medicine with over 30 years of experience in referral medicine and oncology and Barbara Spruce a physician scientist with extensive translational oncology and medicines regulation experience.  Kyrexa’s goal is to deliver a kinder way to treat cancer. We believe that cancer treatment should be available to all pets at their local veterinary practice to ensure that treatment is not restricted by location, budget or family circumstances. Pets can then spend as much as possible of their final days at home and live their remaining life to the fullest. Our global patent covers both humans and dogs and we hope to be able to bring a new way for treating cancer for all those affected. 

What services do we offer?

Kyrexa is developing a first-in-class oral small-molecule immunotherapy for canine cancer that can be used by GP vets. Our drug combines direct anti-tumour, anti-angiogenic and immune-engagement actions in an oral treatment with clear advantages over biologics. Data from a historical human trial has already provided safe doses for dogs. Pilot data in 30 dogs with advanced cancers shows strong tumour response rates with excellent quality of life, providing a huge opportunity to treat more pets with cancer with a drug that has minimal side effects and gives excellent quality of life even in the face of advanced cancers. 

Who can we help?

Our goal is to deliver a new way to treat cancer in dogs initially with the opportunity to expand into other pets and humans. The drug cannot be sold until it has undergone regulatory approvals, however we are working hard to make it available as soon as possible. The drug has the potential to change the face of cancer care.  

How do we support One Medicine?

Our drug started life in the human space for a mental health indication and has been found to have anti-cancer effects. The goal is to use knowledge gained through the human drug development path back into animals allowing us to be confident that it has a role to play. The pathway for animal drug development is shorter and cheaper than that for humans. However the common use of naturally occurring dog cancer as a model for human cancers means that this path should accelerate the opportunities within the human cancer treatment sphere.  

Contact

Name: Clare Knottenbelt

Email Address:

Social media:

Address: 

Website: https://kyrexa.com/